Survivors of childhood cancer need lifelong monitoring for side effects from radiotherapy. However, longitudinal data from routine monitoring is often infrequently and irregularly sampled, and subject to inaccuracies. Due to this, measurements are often studied in isolation, or simple relationships (e.g., linear) are used to impute missing timepoints. In this study, we investigated the potential role of Gaussian Processes (GP) modelling to make population-based and individual predictions, using insulin-like growth factor 1 (IGF-1) measurements as a test case. With training data of 23 patients with a median (range) of 4 (1-16) timepoints we identified a trend within the range of literature reported values. In addition, with 8 test cases, individual predictions were made with an average root mean squared error of 31.9 (10.1 - 62.3) ng/ml and 27.4 (0.02 - 66.1) ng/ml for two approaches. GP modelling may overcome limitations of routine longitudinal data and facilitate analysis of late effects of radiotherapy.

Guidelines for the management of atherosclerotic cardiovascular disease (ASCVD) recommend the use of risk stratification models to identify patients most likely to benefit from cholesterol-lowering and other therapies. These models have differential performance across race and gender groups with inconsistent behavior across studies, potentially resulting in an inequitable distribution of beneficial therapy. In this work, we leverage adversarial learning and a large observational cohort extracted from electronic health records (EHRs) to develop a "fair" ASCVD risk prediction model with reduced variability in error rates across groups. We empirically demonstrate that our approach is capable of aligning the distribution of risk predictions conditioned on the outcome across several groups simultaneously for models built from high-dimensional EHR data. We also discuss the relevance of these results in the context of the empirical trade-off between fairness and model performance.